Lifeboat Foundation

Electronic circuits are found in almost everything from smartphones to spacecraft and are useful in a variety of computational problems from simple addition to determining the trajectories of interplanetary satellites. At Caltech, a group of researchers led by Assistant Professor of Bioengineering Lulu Qian is working to create circuits using not the usual silicon transistors but strands of DNA.

The Qian group has made the technology of DNA circuits accessible to even novice researchers—including undergraduate students—using a software tool they developed called the Seesaw Compiler. Now, they have experimentally demonstrated that the tool can be used to quickly design DNA circuits that can then be built out of cheap “unpurified” DNA strands, following a systematic wet-lab procedure devised by Qian and colleagues.

A paper describing the work appears in the February 23 issue of Nature Communications.

Last week, the US Patent and Trademarks Office ruled on the most-watched patent proceeding of the 21st century: the fight for Crispr-Cas9. The decision was supposed to declare ownership of the rights to the revolutionary gene editing technique. But instead, the patent judge granted sorta-victories to each of the rival parties—a team from UC Berkeley and another with members from both MIT and Harvard University’s Broad Institute. That’s great for those groups (and their spin-off, for-profit gene editing companies with exclusive licenses). But it leaves things a bit murkier for anyone else who wants to turn a buck with gene editing.

The Crispr discoverers now have some authority over who gets to use Crispr, and for what. And while exclusive licenses aren’t rare in biotech, the scope of these do stand out: They cover all the 20,000-plus genes in the human genome. So this week, legal experts are sending a formal request to the Department of Health and Human Services. They want the federal government to step in and bring Crispr back to the people.

Crispr is new, but patent laws governing genetic engineering date back decades. In 1980, shortly after the Supreme Court ruled that genetically engineered microbes were patentable, Congress passed something called the Bayh-Doyle Act. The law gives permission for universities to patent—and license—anything their researchers invented with public funds, making it easier to put those inventions back in the hands of citizens.

DNA, the stuff of life, may very well also pack quite the jolt for engineers trying to advance the development of tiny, low-cost electronic devices.

Much like flipping your light switch at home — –only on a scale 1,000 times smaller than a human hair — –an ASU-led team has now developed the first controllable DNA switch to regulate the flow of electricity within a single, atomic-sized molecule. The new study, led by ASU Biodesign Institute researcher Nongjian Tao, was published in the advanced online journal Nature Communications ( DOI: 10.1038/ncomms14471).

“It has been established that charge transport is possible in DNA, but for a useful device, one wants to be able to turn the charge transport on and off. We achieved this goal by chemically modifying DNA,” said Tao, who directs the Biodesign Center for Bioelectronics and Biosensors and is a professor in the Fulton Schools of Engineering.

Continue reading “Switched-on DNA spark nano-electronic applications” »

The Methuselah Foundation wants to extend healthy life — By advancing tissue engineering and regenerative medicine, they want to create a world where 90-year olds can be as healthy as 50-year olds—by 2030.

Donate to the Methuselah Foundation here at this link

Methuselah Foundation reviewed the progress they made over the past year. Much of what you’ll read in this year in review letter is very late-breaking, and leads us to believe that 2017 will be a very important year in medical developments. 2016 took us a broad step closer to fulfilling our mission statement to “Make 90 the New 50, by 2030”. Why can we say that? For starters, let’s look at several achievements to date that made this year so successful:

Continue reading “Methuselah Foundation making progress to make 90 the new 50 by 2030” »

Orginal press: http://www.prweb.com/releases/2017/02/prweb14062199.htm

Bioquark, Inc., (http://www.bioquark.com) a life sciences company focused on the development of novel biologics for complex regeneration and disease reversion, and SC21 Biotech, (http://www.sc21bio.tech), a biotechnology company focused on translational therapeutic applications of autologous stem cell therapy, have announced a collaboration to focus on novel cellular reprogramming and production approaches for CCR5 Delta32 homozygous cord blood stem cells, for long-term control of HIV via transplantation.

“We are very excited about this collaboration with SC21 Biotech,” said Ira S. Pastor, CEO, Bioquark Inc. “The natural synergy of our cellular reprogramming tools and SC21 Biotech’s translational cell therapy experience, will make for a transformational opportunity in this area of HIV disease control.”

Continue reading “Bioquark Inc. and SC21 Biotech to Collaborate on Novel Cellular Therapies for Long Term HIV Control” »

Rare breeds of chickens could soon come from entirely different types of hens. The University of Edinburgh’s Roslin Institute with help from US biotechnology company Recombinetics used gene editing techniques to create surrogate hens that grow up to produce eggs with all the genetic information of different breeds.

We’ve seen gene editing and transfer techniques used to create better yeast, bigger trees and even glowing pigs, among numerous other examples, but this is believed to be the first gene-edited bird to come out of Europe.

The team used a gene editing tool called TALEN (for transcription activator-like effector nucleases), which is similar to the more widely publicized CRISPR/Cas9, to delete part of a chicken gene called DDX4 that is related to fertility. Hens with this modification did not produce eggs but were healthy in all other ways.

Continue reading “Genetically-engineered hens produce birds of a different feather” »

Mantas from CellAge picks a winner for the iPhone Raffle Reward! ►Campaign Link: https://www.lifespan.io/campaigns/cellage-targeting-senescen…c-biology/ ►Subscribe:
►Reddit AMA: https://www.reddit.com/r/Futurology/comments/5hfmsl/cellage_…ells_with/

Our society has never aged more rapidly – one of the most visible symptoms of the changing demographics is the exponential increase in the incidence of age-related diseases, including cancer, cardiovascular diseases and osteoarthritis. Not only does aging have a negative effect on the quality of life among the elderly but it also causes a significant financial strain on both private and public sectors. As the proportion of older people is increasing so is health care spending. According to a WHO analysis, the annual number of new cancer cases is projected to rise to 17 million by 2020, and reach 27 million by 2030. Similar trends are clearly visible in other age-related diseases such as cardiovascular disease. Few effective treatments addressing these challenges are currently available and most of them focus on a single disease rather than adopting a more holistic approach to aging.

Continue reading “CellAge Campaign: iPhone Reward Raffle Draw” »

Cool story!

Biohackers push back as the scientific establishment charts a course through the ethics of genetic interference.

For those interested in life extension and bionic / cyborg type enhancements, this CMU Robotics Institute Seminar gives an overview of the background and current developments in artificial vision. José Alain Sahel MD is a world leading ophthalmologist with a lengthy bio and numerous honors and appointments.

In the future, if you’re going blind, these sight restoration technologies may be used to remediate your vision loss.

Three major ideas are covered. 1) Implanting arrays of tiny 3-color LEDs under a failed retina to stimulate still-okay cells, and 2) using gene therapy to express a novel photoreceptor, borrowed from algae, to restore a form of sight to failed cells. These can be done together. Lots of studies in mice, primates, and humans. Some coverage is also given to 3) directly implanting electronics in the brain to send complete images to vision centers, but this is still at an early stage.

Continue reading “Artificial Vision, Artificial Retina, Optogenetics, José Alain Sahel MD, CMU RI Seminar” »